dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma
ConclusiondCas9/CRISPR is a viable method of epigenetic editing, using the DNMT3A catalytic domain. This study provides initial proof-of-principle for CRISPR technology applications in malignant glioma, laying groundwork for subsequent translational studies, with implications for future epigenetic editing-based clinical applications.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Tumor | Cancer & Oncology | Gastroschisis Repair | Glioma | Neurology | Study | Temodar